- The study investigated if telitacicept, targeting BAFF and APRIL, could reduce proteinuria in IgA nephropathy.
- This phase 3, randomized, placebo-controlled trial enrolled 318 adults with biopsy-proven IgA nephropathy and proteinuria.
- Telitacicept reduced 24-hour urinary protein-to-creatinine ratio by -55.0% (95% CI, -61.3 to -47.6; P<0.001) versus placebo.
- The authors concluded telitacicept significantly reduced proteinuria in high-risk IgA nephropathy patients over 39 weeks.
- This suggests telitacicept could offer a therapeutic option for managing proteinuria in IgA nephropathy.
Navigating IgA Nephropathy: The Search for Targeted Therapies
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis globally, often progressing to end-stage renal disease [1, 2, 3]. Despite supportive care with blood pressure control and renin-angiotensin system inhibitors, many adults with IgAN exhibit persistent proteinuria, a key indicator of high risk for renal function decline [4, 5]. The pathogenesis, which involves B-cell activation and the production of pathogenic galactose-deficient IgA1, has become a focus for targeted immunomodulatory therapies [6, 7]. While several agents are in development, optimal strategies for slowing disease progression remain an area of active investigation [8, 9, 10]. A recent phase 3 trial now provides data on a therapy designed to inhibit two central B-cell signaling pathways.
Targeting B-Cell Pathways in IgA Nephropathy
The pathophysiology of IgA nephropathy is driven by dysregulated B-cell activity. Two specific cytokines, B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), are key mediators in this process, promoting B-cell survival and differentiation that lead to the production of pathogenic IgA1. Given their central role, these pathways present a logical therapeutic target. The investigational agent telitacicept is a fusion protein engineered to bind and neutralize both BAFF and APRIL. By simultaneously inhibiting these two cytokines, the therapy aims to interrupt the aberrant B-cell activation and subsequent immune complex formation that characterize the disease.
Trial Design and Patient Cohort
The new findings emerge from a prespecified interim analysis of a phase 3, multicenter, double-blind, randomized, placebo-controlled trial. The study enrolled adults with biopsy-proven IgA nephropathy and persistent proteinuria of ≥1.0 g per day, despite receiving appropriate supportive care. This inclusion criterion is clinically significant, as it specifically selects for a patient population at high risk for disease progression. A total of 318 patients were randomized in a 1:1 ratio, with 159 assigned to receive subcutaneous once-weekly telitacicept (240 mg) and 159 to a matching placebo. The primary endpoint was the change in the 24-hour urinary protein-to-creatinine ratio from baseline to 39 weeks, a standard surrogate marker for assessing treatment efficacy in glomerular diseases.
Significant Reduction in Proteinuria Observed
The interim analysis at 39 weeks demonstrated a substantial treatment effect on the primary endpoint. Patients receiving telitacicept had a mean percentage change in the 24-hour urinary protein-to-creatinine ratio of -58.9% from baseline. In contrast, the placebo group showed a minimal change of -8.8% over the same period. This corresponded to a relative difference between the groups of -55.0% (95% confidence interval [CI], -61.3 to -47.6; P<0.001) in favor of telitacicept. The magnitude and statistical significance of this reduction in proteinuria suggest a potent biological effect of the drug in this high-risk patient population.
Impact on Kidney Function and Safety Profile
In addition to reducing proteinuria, the study assessed the agent's effect on preserving kidney function. At 39 weeks, the mean percentage change in estimated glomerular filtration rate (eGFR) from baseline was -1.0% (95% CI, -3.2 to 1.2) in the telitacicept group, indicating stable renal function. This contrasted with a more pronounced decline in the placebo group, which experienced a mean eGFR change of -7.7% (95% CI, -9.9 to -5.4). Regarding safety, adverse events were more frequent with telitacicept than with placebo (89.3% vs. 78.6% of patients). However, serious adverse events were notably less common in the telitacicept arm (2.5%) compared to the placebo arm (8.2%). The authors reported no unexpected safety signals associated with the treatment.
Funding and Trial Registration
The phase 3 trial investigating telitacicept in IgA nephropathy was funded by RemeGen, the pharmaceutical company developing the dual B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) antagonist. The study is registered at ClinicalTrials.gov under the identifier NCT05799287 and is known as the TELIGAN trial.
References
1. Tian Z, Yang Y, Huang M, et al. Efficacy and safety of BAFF/APRIL dual antagonists in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials.. BMC nephrology. 2025. doi:10.1186/s12882-025-04689-w
2. Chen B, Zhu Y, Yang Y, Xu G. Efficacy and safety of agents for IgA nephropathy: a network meta-analysis of randomized controlled trials. Frontiers in Medicine. 2025. doi:10.3389/fmed.2025.1515723
3. Zhang H, Ren S, Hu J, Li G. Long-term renal survival in patients with IgA nephropathy: a systematic review. Renal Failure. 2024. doi:10.1080/0886022x.2024.2394636
4. Lv J, Liu L, Wang W, et al. Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial.. The New England journal of medicine. 2026. doi:10.1056/NEJMoa2514415
5. Cheng X, Yu S, Gou W, Xu Y, Yang L, Dai B. Precision Treatment of IgA Nephropathy Based on a New Framework: Angiorenal Protection, Immunity Inhibition, B-Cell/Plasma-Cell Modulation, and Complement Inhibition. Kidney Diseases. 2025. doi:10.1159/000544998
6. Ma J, Xing J, Zhang Y, Liu G. Efficacy and safety of biologic agents for IgA nephropathy: A protocol for systematic review and meta-analysis. PLoS ONE. 2024. doi:10.1371/journal.pone.0298732
7. Konda R, Rajasekaran A, Rizk DV. What do clinical trials teach us about the pathophysiology of human IgA nephropathy?. Nephrology Dialysis Transplantation. 2025. doi:10.1093/ndt/gfaf144
8. Gao G, Iida Y, Beaini C, Ghanem A, Varma S, Elsharkawy M. Efficacy of Immunosuppression Therapy in Primary IgA Nephropathy in Adults: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. 2025. doi:10.69854/jcq.2025.0011
9. Ratan P, Kritika F, Ratan K, Kumari N. #810 Efficacy and safety of telitacicept in IgA nephropathy: a systematic review and meta-analysis. Nephrology, Dialysis and Transplantation. 2025. doi:10.1093/ndt/gfaf116.0285
10. Alroshodi A, Al-Harbi FA, Alkuwaiti MA, et al. Comparative Efficacy and Safety of Pharmacological Interventions for IgA Nephropathy: A Systematic Review and Meta-Analysis. Medicina. 2025. doi:10.3390/medicina61122233